Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2022	Mar. 31, 2021
Operating activities:
Net loss	$ (37,417)	$ (8,991)
Adjustments to reconcile net loss to cash used in operating activities:
Acquired in-process research and development	23,049
Depreciation and amortization	25	17
Stock-based compensation	1,298	1,044
Net unrealized (gain) loss on foreign currency transactions	(140)	50
Amortization of term loan discount and issuance costs	48	64
Amortization/accretion of investments, net	47	100
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(553)	481
Right-of-use assets, operating leases	104
Accounts payable	2,692	(489)
Accrued expenses	(1,218)	(220)
Operating lease liabilities	(69)
Net cash used in operating activities	(12,134)	(7,944)
Investing activities:
Purchases of property and equipment	(223)
Purchases of short-term investments	(14,962)	(7,605)
Maturities of short-term investments	2,500	12,465
Net cash (used in) provided by investing activities	(11,985)	4,860
Financing activities:
Proceeds from registered direct offering, net of offering costs		29,960
Proceeds from exercise of stock options		4
Net cash provided by financing activities		29,964
Effect of exchange rate changes on cash and cash equivalents	(3)	(1)
Net (decrease) in cash and cash equivalents	(24,122)	26,879
Cash and cash equivalents at beginning of period	50,366	23,982
Cash and cash equivalents at end of period	26,244	50,861
Supplemental disclosures of non-cash activities:
Property and equipment in accounts payable	36
Registered direct offering issuance costs in accounts payable		$ 50
Bioniz
Investing activities:
Cash acquired in Bioniz acquisition	700
Supplemental disclosures of non-cash activities:
Fair value of Bioniz assets acquired	23,049
Issuance of common stock for Bioniz acquisition	22,542
Bioniz net liabilities assumed	$ 507